125 related articles for article (PubMed ID: 18336238)
1. Apo A-1 mimetic peptides as atheroprotective agents in murine models.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Fogelman AM
Curr Drug Targets; 2008 Mar; 9(3):204-9. PubMed ID: 18336238
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis.
Sherman CB; Peterson SJ; Frishman WH
Cardiol Rev; 2010; 18(3):141-7. PubMed ID: 20395699
[TBL] [Abstract][Full Text] [Related]
3. Apoprotein A-I mimetic peptides and their potential anti-atherogenic mechanisms of action.
Getz GS; Wool GD; Reardon CA
Curr Opin Lipidol; 2009 Jun; 20(3):171-5. PubMed ID: 19373084
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein A-I mimetic peptides.
Van Lenten BJ; Wagner AC; Anantharamaiah GM; Navab M; Reddy ST; Buga GM; Fogelman AM
Curr Atheroscler Rep; 2009 Jan; 11(1):52-7. PubMed ID: 19080728
[TBL] [Abstract][Full Text] [Related]
5. Multiple indications for anti-inflammatory apolipoprotein mimetic peptides.
Van Lenten BJ; Navab M; Anantharamaiah GM; Buga GM; Reddy ST; Fogelman AM
Curr Opin Investig Drugs; 2008 Nov; 9(11):1157-62. PubMed ID: 18951294
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein A-I mimetic peptides.
Hovingh GK; Bochem AE; Kastelein JJ
Curr Opin Lipidol; 2010 Dec; 21(6):481-6. PubMed ID: 21042216
[TBL] [Abstract][Full Text] [Related]
7. The promise of apolipoprotein A-I mimetics.
Mendez AJ
Curr Opin Endocrinol Diabetes Obes; 2010 Apr; 17(2):171-6. PubMed ID: 20125002
[TBL] [Abstract][Full Text] [Related]
8. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Datta G; Garber D; Fogelman AM
Curr Opin Lipidol; 2004 Dec; 15(6):645-9. PubMed ID: 15529023
[TBL] [Abstract][Full Text] [Related]
9. Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides.
Gomaraschi M; Calabresi L; Rossoni G; Iametti S; Franceschini G; Stonik JA; Remaley AT
J Pharmacol Exp Ther; 2008 Feb; 324(2):776-83. PubMed ID: 18042829
[TBL] [Abstract][Full Text] [Related]
10. The role of dysfunctional HDL in atherosclerosis.
Navab M; Reddy ST; Van Lenten BJ; Anantharamaiah GM; Fogelman AM
J Lipid Res; 2009 Apr; 50 Suppl(Suppl):S145-9. PubMed ID: 18955731
[TBL] [Abstract][Full Text] [Related]
11. High-Density Lipoprotein-Targeted Therapy and Apolipoprotein A-I Mimetic Peptides.
Uehara Y; Chiesa G; Saku K
Circ J; 2015; 79(12):2523-8. PubMed ID: 26548857
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention.
Navab M; Anantharamaiah GM; Reddy ST; Fogelman AM
Nat Clin Pract Cardiovasc Med; 2006 Oct; 3(10):540-7. PubMed ID: 16990839
[TBL] [Abstract][Full Text] [Related]
13. Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides.
Anantharamaiah GM; Mishra VK; Garber DW; Datta G; Handattu SP; Palgunachari MN; Chaddha M; Navab M; Reddy ST; Segrest JP; Fogelman AM
J Lipid Res; 2007 Sep; 48(9):1915-23. PubMed ID: 17570869
[TBL] [Abstract][Full Text] [Related]
14. The effect of apolipoprotein mimetic peptides in inflammatory disorders other than atherosclerosis.
Navab M; Anantharamaiah GM; Fogelman AM
Trends Cardiovasc Med; 2008 Feb; 18(2):61-6. PubMed ID: 18308197
[TBL] [Abstract][Full Text] [Related]
15. Inflammation/oxidation in chronic rejection: apolipoprotein a-i mimetic peptide reduces chronic rejection of transplanted hearts.
Hsieh GR; Schnickel GT; Garcia C; Shefizadeh A; Fishbein MC; Ardehali A
Transplantation; 2007 Jul; 84(2):238-43. PubMed ID: 17667816
[TBL] [Abstract][Full Text] [Related]
16. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I.
Van Lenten BJ; Wagner AC; Jung CL; Ruchala P; Waring AJ; Lehrer RI; Watson AD; Hama S; Navab M; Anantharamaiah GM; Fogelman AM
J Lipid Res; 2008 Nov; 49(11):2302-11. PubMed ID: 18621920
[TBL] [Abstract][Full Text] [Related]
17. The dual nature of HDL: Anti-Inflammatory and pro-Inflammatory.
Namiri-Kalantari R; Gao F; Chattopadhyay A; Wheeler AA; Navab KD; Farias-Eisner R; Reddy ST
Biofactors; 2015 May; 41(3):153-9. PubMed ID: 26072738
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.
McGrath KC; Li X; Twigg SM; Heather AK
PLoS One; 2020; 15(1):e0226931. PubMed ID: 31914125
[TBL] [Abstract][Full Text] [Related]
19. Recombinant high-density lipoproteins and their use in cardiovascular diseases.
Cao YN; Xu L; Han YC; Wang YN; Liu G; Qi R
Drug Discov Today; 2017 Jan; 22(1):180-185. PubMed ID: 27591840
[TBL] [Abstract][Full Text] [Related]
20. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol.
Navab M; Anantharamaiah GM; Hama S; Garber DW; Chaddha M; Hough G; Lallone R; Fogelman AM
Circulation; 2002 Jan; 105(3):290-2. PubMed ID: 11804981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
